Last reviewed · How we verify
NCT04128657: MA_LARSWEX
Validation of the Moroccan Arabic Version of the Low Anterior Resection Syndrome (LARS) and Wexner Score of Continence Among Rectal Cancer Patients
trial testing MA_LARS in Rectal Cancer Patients in 143 participants. Completed in 31 October 2019.
31 October 2019
Quick facts
| Lead sponsor | Moroccan Society of Surgery |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 143 |
| Start date | 1 January 2019 |
| Primary completion | 31 October 2019 |
| Estimated completion | 31 October 2019 |
| Sites | 2 locations across Morocco |
Drugs / interventions tested
- MA_LARS
Conditions studied
- Rectal Cancer Patients — all drugs for Rectal Cancer Patients →
Sponsor
Moroccan Society of Surgery
Who can join
18 and older, any sex, with Rectal Cancer Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the past decade, colorectal cancer management improved considerably with total mesorectal excision as well as the multidisciplinary management relying on neoadjuvant radiochemotherapy. This forward leap is currently responsible for an increase in the survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the surgical approach is now more inclined towards sphincter preserving procedures, which allows the conservation of body image but can have negative bowel function repercussions consisting of urgency and incontinence ; all these terms encompassed in the low anterior resection syndrome. In the light of these findings many studies developed assessment tools in order to objectively measure this functional alteration among which are the low anterior resection syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel function after sphincter-preserving surgery are now translated and validated into various languages and used in different countries. The LARS score relies on the frequency of the symptoms and allows the categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score relies on the examination of the frequency of three types of fecal incontinence (solid, liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency options ranging from never (score 0) through to always (meaning at least once per day; score 4). The score ranges from 0 (perfect continence) to 20 (complete incontinence). The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan arabic dialect.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Validation of the Moroccan arabic version of the low anterior resection syndrome score.
Essangri H, Majbar MA, Benkabbou A, Amrani L, et al · · 2020 · cited 2× · PMID 33050906 · DOI 10.1186/s12876-020-01463-0
Verify or expand the search:
- PubMed search for NCT04128657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer Patients
Currently open trials in the same condition.
- NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
- NCT07198165 — SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC · Phase 2 · recruiting
- NCT07337811 — Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergo · NA · recruiting
- NCT06647680 — Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） · Phase 2 · recruiting
- NCT06911684 — Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC · Phase 2 · recruiting
Other Moroccan Society of Surgery trials
Trials by the same sponsor.
- NCT04607577 — Cross-cultural Adaptation and Validation in Moroccan Arabic Dialect "Darija" of the QoR-15 Postoperative Recovery Qualit · unknown
- NCT05494281 — Serratus Anterior Plane Block to Prevent Chronic Postoperative Pain in Breast Cancer · NA · unknown
- NCT04130568 — Translation and Adaptation of Learning Organisation Survey for French Speaking Countries · completed
- NCT04000802 — Evaluation of the Decision-making During Multidisciplinary Meetings for Digestive Cancers · completed
- NCT05286411 — Evaluation of the Implementation of a Quality Improvement Program Through Morbidity and Mortality Reviews · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04128657 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moroccan Society of Surgery
- Last refreshed: 20 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04128657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing